Role of NF-κB in CB1 and CB2 activation by GEM and in the antiproliferative synergism by GEM/cannabinoids. (a) Panc1 cells were seeded in 60-mm plates and incubated overnight. Cells were pretreated with 5 μg/ml ActD for 1 h, then 2 μM GEM was added, and the treatments prolonged up to 16 h. Total RNA extraction and real-time PCR were performed, as described in Materials and Methods. Values are the means of triplicate samples from four independent experiments (±S.D.). (b) qPCR analysis of CB1 and CB2 mRNAs from cells treated with 2 μM GEM or 10 μg/ml IL-1. In all, 10 mM NAC, 10 μM BAY, 100 μM PDTC, or 100 μM MG132, where indicated, were added 1 h before treatments. CB1 and CB2 mRNAs were analyzed at 16 h. Values are the means of triplicate samples from three independent experiments (±S.D.). Statistical analysis: P<0.001, control versus GEM or GEM+NAC and P<0.001, GEM versus GEM+MG132, GEM+BAY, or GEM+PDTC. P<0.001, IL-1 versus IL-1+MG132 (for both CB1 and CB2). (c) Analysis of the antiproliferative synergism by 2 μM GEM and 40 μM GW, 225 μM ACPA, or 40 μM SR1 in the absence or presence of 100 nM MG132 or 1 μM BAY. Values are the means of three independent experiments (±S.D.). Statistical analysis for total synergism (0.3<CI<1): P<0.001, GEM+GW versus GEM+GW+BAY; P<0.001, GEM+ACPA versus GEM+ACPA+BAY; P<0.001, GEM+SR1 versus GEM+SR1+MG or GEM+SR1+BAY; P<0.05, GEM+GW versus GEM+GW+MG; and P<0.05, GEM+ACPA versus GEM+ACPA+MG. Statistical analysis for high synergism (CI<0.3): P<0.001, GEM+GW versus GEM+GW+MG or GEM+GW+BAY; P<0.001, GEM+SR1 versus GEM+SR1+BAY; P<0.01, GEM+ACPA versus GEM+ACPA+BAY; P<0.01, GEM+SR1 versus GEM+SR1+BAY; and P<0.05, GEM+ACPA versus GEM+ACPA+MG